Italian Journal of Dermatology and Venereology 2022 February;157(1):1-12

DOI: 10.23736/S2784-8671.21.07129-2

lingua: Inglese

Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)

Antonio COSTANZO ^{1, 2}, Paolo AMERIO ³, Riccardo ASERO ⁴, Andrea CHIRICOZZI ^{5, 6}, Monica CORAZZA ⁷, Antonio CRISTAUDO ⁸, Francesco CUSANO ⁹, Silvia M. FERRUCCI ¹⁰, Eustachio NETTIS ¹¹, Annalisa PATRIZI ^{12, 13} ✉, Cataldo PATRUNO ¹⁴, Ketty PERIS ^{5, 6}, Mario PICOZZA ¹⁵, Luca STINGENI ¹⁶, Giampiero GIROLOMONI ¹⁷, on behalf of Italian AD Study Group

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; ² Unit of Dermatology, IRCCS Humanitas Clinic, Rozzano, Milan, Italy; ³ Unit of Dermatology, Department of Medicine and Aging Science, G. D’Annunzio University, Chieti, Chieti-Pescara, Italy; ⁴ Department of Allergology, San Carlo Clinic, Paderno Dugnano, Milan, Italy; ⁵ Unit of Dermatology, Department of Surgical and Medical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy; ⁶ Unit of Dermatology, Department of Medicine and Translational Surgery, Sacred Heart Catholic University, Rome, Italy; ⁷ Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; ⁸ Department of Dermatology, IRCCS San Gallicano Dermatological Institute, Rome, Italy; ⁹ Unit of Dermatology, San Pio Hospital - G. Rummo Hospital, Benevento, Italy; ¹⁰ Section of Dermatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹¹ Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, Aldo Moro University, Bari, Italy; ¹² Dermatology of Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy; ¹³ Unit of Dermatology, IRCCS S. Orsola-Malpighi Polyclinic, Bologna, Italy; ¹⁴ Department of Health Sciences, Magna Grecia University, Catanzaro, Italy; ¹⁵ National Association of Atopic Dermatitis (ANDeA), Prato, Italy; ¹⁶ Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; ¹⁷ Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy

HTML PDF Materiale_Supplementare

Atopic dermatitis (AD) is a common chronic-relapsing inflammatory skin disease, burdened by various comorbidities. AD most commonly occurs in children but may persist or present in adulthood becoming a lifelong condition. Therefore, AD requires an effective long-term treatment improving disease signs and symptoms but also of patients’ quality of life (QoL). However continuous long-term use of most traditional AD immunosuppressive treatments is not recommended for safety reasons or insufficient efficacy data. Despite the available guidelines, there is still need for knowledge of AD long-term treatment, taking into account new disease measures and recent treatment options. Five Italian scientific societies implemented a joint consensus procedure to define the most appropriate clinical practice for the long-term management of adult moderate-severe AD. Through a modified Delphi procedure, consensus was reached by overall 51 Italian dermatologists and allergists (The Italian AD Study Group) experienced in the management of adult AD on 14 statements covering three AD areas of interest, namely diagnosis, definition of disease severity and clinimetrics, and a treat-to-target approach. This paper reports and discusses the agreed statements, which define disease and patient impact measures, therapeutic approach, and a treatment decision algorithm to support clinicians in the long-term management of adult patients with moderate-to-severe AD in their daily clinical practice.

KEY WORDS: Dermatitis, atopic; Adult; Diagnosis; Biological products; Dupilumab

inizio pagina

Publication History

Issue published online: February 17, 2022
Article first published online: December 21, 2021
Manuscript accepted: November 16, 2021
Manuscript revised: October 15, 2021
Manuscript received: June 18, 2021

Per citare questo articolo

Costanzo A, Amerio P, Asero R, Chiricozzi A, Corazza M, Cristaudo A, et al; Italian AD Study Group. Long-term management of moderate-to-severe adult atopic dermatitis. Ital J Dermatol Venereol 2022;157:1-12. DOI: 10.23736/S2784-8671.21.07129-2

Italian AD Study Group

Giuseppe F. AMORUSO (Unit of Dermatology, Annunziata-Mariano Santo Hospital, Cosenza, Italy); Giuseppe ARGENZIANO (Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples, Italy); Riccardo BALESTRI (Division of Dermatology, Hospital of Trento, Trento, Italy); Anna BELLONI FORTINA (Unit of Dermatology, Department of Clinical Medicine, Hospital of Padua, Padua, Italy); Laura BONZANO (Unit of Dermatology, IRCCS of Reggio Emilia, Reggio Emilia, Italy); Angelo M. D’ERME (Unit of Dermatology, Hospital of Livorno, Livorno, Italy); Vito DI LERNIA (Unit of Dermatology, Arcispedale Santa Maria Nuova, IRCCS of Reggio Emilia, Reggio Emilia, Italy); Klaus EISENDLE (Department of Dermatology, Hospital of Bolzano, Bolzano, Italy); Enzo ERRICHETTI (Institute of Dermatology, “Santa Maria della Misericordia” University Hospital, Udine, Italy); Maria ESPOSITO (Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila. L’Aquila Italy); Gabriella FABBROCINI (Unit of Clinical Dermatology, University of Naples Federico II, Naples, Italy); Maria L. FLORI (Unit of Dermatology and Venereology, Department of Surgery and Neuroscience, Università of Siena, Siena, Italy); Caterina FOTI (Unit of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy); Alessandro GATTI (Unit of Dermatology, Ca’ Foncello Hospital, Treviso, Italy); Teresa GRIECO (Unit of Dermatology, Santa Croce Hospital, Fano, Italy); Fabrizio GUARNERI (Section of Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy); Serena LEMBO (Department of Medicine and Surgery, University of Salerno, Salerno, Italy); Antonino MUSARRA (ASP Reggio Calabria, Reggio Calabria, Italy); Maria L. MUSUMECI (Dermatologic Clinic, University of Catania, Catania, Italy; Unit of Dermatology, P.O. G. Rodolico, G. Rodolico-San Marco University Hospital, Catania, Italy); Maddalena NAPOLITANO (Department of Medicine and Health Sciences V. Tiberio, University of Molise, Campobasso, Italy); Annamaria OFFIDANI (Unit of Dermatology, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy); Michela ORTONCELLI (Città della Salute e della Scienza, University of Turin, Turin, Italy); Giovanni PAOLINO (Unit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy); Vincenzo PATELLA (School of Specialization of Allergology and Clinical Immunology, University of Naples Federico II, Naples, Italy); Ginevra PERTUSI (Department of Dermatology, S. Andrea Hospital, Vercelli, Italy); Angelo PICCIRILLO (Unit of Dermatology, S. Carlo Hospital, Potenza, Italy); Paolo D. PIGATTO (Unit of Clinical Dermatology, IRCCS Galeazzi Orthopedic Institute, Milan, Italy; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy); Viviana PIRAS (Unit of Dermatology. Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy); Marco ROMANELLI (Dermatological Clinic, University of Pisa, Pisa, Italy); Rosanna SATTA (Section of Dermatology, Department of Medical and Surgical Sciences, University of Sassari, Sassari, Italy); Claudio SCIARRONE (Unit of Dermatology, Papardo Hospital, Messina, Italy); Donatella SORDI (Unit of Dermatology, IDI-IRCCS-FLMM, Rome, Italy); Rossana TIBERIO (Dermatological Clinic, Maggiore della Carità Hospital, Novara, Italy); Ersilia TOLINO (Unit of Dermatology, A. Fiorini Hospital, Terracina, Latina, Italy); Shohreh ZAVAREH ARDESTANI (Unit of Dermatology, Ospedali Riuniti Marche Nord Hospital, Pesaro, Italy).

Corresponding author e-mail

annalisa.patrizi@unibo.it

I TUOI DATI

I TUOI ORDINI

CESTINO ACQUISTI

COME ORDINARE

I TUOI ABBONAMENTI

I TUOI ARTICOLI

I TUOI EBOOK

COUPON

ACCESSIBILITÀ

Italian Journal of Dermatology and Venereology 2022 February;157(1):1-12

Publication History

Per citare questo articolo

Italian AD Study Group

Corresponding author e-mail

Share